Citations

Clear

2358 citation(s) found for "Yu, Long".

Surgeon-patient Sex Concordance and Long-term Clinical Outcomes and Costs Following Common Surgeries
Thomas, Hannah S. , Satkunasivam, Raj , Coburn, Natalie, Wright, Frances C. , Salles, Arghavan, Riveros, Carlos , Titus, Renil S. , Velasquez, Eusebio Luna, Armstrong, Kathleen, Detsky, Allan S. , Wallis, Christopher J.D., Lin, Lauren, O’Connell, Clare , Coburn, Natalie, Salles, Arghavan , Heybati, Kiyan , Luckenbaugh, Amy N. , Mundra, Vatsala , Velásquez, Eusebio Jesús Luna , Armstrong, Kathleen , Jerath, Angela , Wallis, Christopher J.D.

Mayo Clinic

Annals of Surgery | March 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000007047 Get It

Objective: To evaluate the associations between surgeon-patient sex concordance, long-term clinical outcomes and healthcare costs. Background Data: Emerging data suggest surgeon-patient sex concordance may improve short-term outcomes, especially for female patients, yet its long-term effects remain unknown. Methods: We conducted a population-based retrospective cohort study of adults undergoing common surgeries in Ontario, Canada (2007-2019). Patients were followed for 90 and 365 days. Surgeon-patient sex concordance was categorized into four dyads. Multivariate generalized estimating equations clustered by procedure type evaluated composite and individual (complications, readmission, mortality) clinical outcomes and healthcare costs. Results: A total of 1,165,711 patients were included. Female patients treated by male surgeons, compared with female surgeons, were more likely to experience an adverse composite event (90 d: aOR 1.12, 95% CI 1.08–1.17, P <0.001; 365 d: aOR 1.09, 95% CI 1.05–1.14, P <0.001), with no association among male patients (90 d: aOR 1.00, 95% CI 0.94–1.05, P =0.89; 365 d: 0.99, 95% CI 0.92–1.07, P =0.87). Long-term total healthcare costs were greater for patients treated by male surgeons - an effect seen in both male patients (90 d: aRR 1.08, 95% CI 1.03-1.14, P =0.002 and 365 d: aRR 1.08, 95% CI 1.02-1.14, P =0.007) and female patients (90 d: aRR 1.10, 95% CI 1.05-1.14, P <0.001, 365 d: aRR 1.09, 95% CI 1.05-1.14, P <0.001). Conclusions: Surgeon-patient sex concordance was associated with improved long-term outcomes for female, but not male, patients, and female surgeons’ patients had lower healthcare costs. Given these benefits, further investigation into the mechanisms driving these outcomes is warranted.
Long-term benzodiazepine use is associated with poorer cognitive function in schizophrenia: Findings from the SALT-C cohort
Liu, Caiping , Zhang, Lei, Pan, Qiyang, Shi, Yue, Yu, Wenjuan , Li, Guanjun , Liu, Caiping, Zhang, Lei , Li, Guanjun, Li, Huafang

Mayo Clinic

No container title available | March 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8797752/v1 Get It

Abstract Background The association between long-term use of benzodiazepines (BDZs) and cognitive function in patients with schizophrenia has not been fully characterized. This study aimed to investigate the relationship between long-term BDZs use and cognitive impairment in schizophrenia. Methods Data were derived from an observational study of treatment with atypical antipsychotics in Chinese patients with schizophrenia (SALT-C). Fifty-seven patients with long-term use of BDZs (≥ 60 days) were included, and 57 BDZs non-users were matched using propensity scores for age, sex, disease duration, and atypical antipsychotics received. Cognitive impairment was assessed using the Montreal Cognitive Assessment (MoCA); psychotic symptoms, illness severity, and psychosocial functioning were assessed with the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression-Severity (CGI-S) scale, and the Personal and Social Performance (PSP) scale. Between-group comparisons were performed using independent-samples t-tests or Mann–Whitney U tests. Multivariate analysis was performed using binary logistic regression. Results The long-term BDZs user group showed a significantly lower total MoCA score [16.02 (6.69)] than the BDZs non-user group [19.33 (7.11)] (P = 0.012). No significant between-group differences were observed in total scores on the PANSS, CGI-S, or PSP (all P > 0.05). Long-term BDZs use was independently associated with cognitive impairment (OR = 7.728, P = 0.017), whereas years of education was negatively associated with cognitive impairment (OR = 0.740, P = 0.007). Conclusions Long-term BDZs use is associated with poorer cognitive performance in patients with schizophrenia, suggesting that cognitive function should be monitored during BDZs treatment in this population.
Long-term stability of language with remapping in patients with medically refractory epilepsy
Serafini, Sandra, Sexton, Daniel P., Lu, Feihan , Miller, Kai, Hodgkinson, Luqman Mushila, Andrews, Edna, Madigan, David , Ga, Ojemann, Grant, Gerald A. , Gramer, Robert , Miller, Kai J. , Hodgkinson, Luqman Mushila

Mayo Clinic

Journal of Neurosurgery | March 7, 2026 | Volume: 144 | Issue: 6 | Pages: 1385-1393

10.3171/2025.10.jns251114 | PMID 41791116 Get It

OBJECTIVE Electrical stimulation mapping is a widely used technique to determine functional localization for medically refractory epilepsy. Sites where stimulation interferes with naming are often focal regions of the frontal and temporal cortex. The extent to which these crucial sites remain in the same location over time in an individual adult patient has not yet been established. The aim of this study was to determine whether cortical naming sites identified using stimulation mapping are stable in their anatomical location over time in adult patients with medically refractory epilepsy. METHODS Twenty-two patients who underwent electrical stimulation mapping for medically refractory epilepsy during surgical interventions separated by more than 1 year between 1967 and 2005 were included. A median of 8.35 years elapsed between mappings. The mean age at the first operation was 27.7 (range 10–39) years. Fourteen patients were female. Mapping occurred under two different conditions: intraoperatively in procedures conducted under local anesthesia or extraoperatively through implanted grid electrodes. A Bayesian hierarchical model of language site locations across repeated interventions was used to assess the stability of locations of stimulation-evoked interference in language naming. RESULTS Sites where electrical stimulation interferes with language naming were separated by a median of 0.6 cm between the 2 mappings. Eighty-six percent of the mapped sites related to language naming at the second operation were within 1.5 cm of a site identified at the first operation, 61% within 1 cm, and 36% within 0.5 cm. However, in 2 patients, none of the identified language naming sites at the second operation were within 1.5 cm of the sites from the first operation. CONCLUSIONS This unique, long-term series of neurosurgical mappings reveals that language naming sites in the cortex of adult patients with epilepsy show substantial long-term stability over many years. However, rare relocation of these sites does occur in some patients over many years.
Long-Term Infant Outcomes After In Utero Biologic Exposure: Results From the Pregnancy Inflammatory Disease Neonatal Outcomes Registry
Kohli, Arushi , Long, M, Beaulieu, Dawn B., Kane, S, Mahadevan, Uma, Kane, Sunanda V. , Mahadevan, Uma

Mayo Clinic

American Journal of Gastroenterology | March 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000003991 | PMID 41789805 Get It

INTRODUCTION: Long-term data are needed for offspring exposed in utero to medications for inflammatory bowel disease (IBD). METHODS: We used a prospective cohort of pregnant women with IBD and their offspring (Pregnancy in IBD and Neonatal Outcomes) to compare rates of serious infection, congenital malformations, and developmental delay by medication exposures. RESULTS: We included 438 offspring with at least 4 years of follow-up. No differences in adverse outcomes were observed by medication. Preterm birth, but not specific drug exposure, was associated with infection risk. Breastfeeding was not associated with serious infection differences. DISCUSSION: These findings support the use of effective IBD therapies throughout pregnancy.
General Radiographic Artifacts: A Visual Review
Long, Zaiyang , Ranschau, Lindsay M. , Lucas, Jill, Broski, S. M., Schueler, Beth A. , Lucas, Jill M, Lucas, Jill M., Broski, Stephen M.

Mayo Clinic

RadioGraphics | March 5, 2026 | Volume: 46 | Issue: 4 | Pages: No page available

10.1148/rg.250177 | PMID 41785120 Get It

This slide presentation uses real-world examples from diverse modern systems to categorize digital radiographic artifacts by likely cause and outlines investigation and mitigation strategies to improve troubleshooting, artifact prevention, and patient care.
Artificial intelligence-enabled cardiac volumetry for opportunistic screening of cardiomegaly on chest CT: clinical validation with echocardiography
Fan, Christopher , Scanio, Angelo , Yokoo, Patrícia , Wiessman, Maya , Lewis, Matthew A. , Xi, Yin, Duan, Xinhui, McColl, Roderick M, Kay, Fernando Uliana , Fan, Christopher M , Abbara, Suhny , Kay, Fernando , Long, Michael, Duan, Xinhui , McColl, Roderick W. , Peshock, Ronald M.

Mayo Clinic

Radiology Advances | March 3, 2026 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/radadv/umag013 | PMID 41890626 Get It

Abstract Background Cardiomegaly is a clinically significant incidental finding on chest computed tomography (CT) associated with heart failure, arrhythmias, and sudden cardiac death. Qualitative radiologist assessment is variable, and automated AI tools may enable objective opportunistic cardiac volumetry. Purpose To evaluate whether AI-enabled total cardiac volume (TCVAI) derived from non-ECG-gated, non-contrast chest CT can identify cardiomegaly as defined by echocardiography. Materials and Methods This retrospective study included 307 consecutive patients (median age, 67 years; 56% male) who underwent non-contrast chest CT at a single center on 7 scanner types (4 vendors) and clinically indicated echocardiography within 31 days. A commercially available AI tool (AI-Rad Companion, Siemens Healthineers) automatically quantified TCVAI, indexed to body surface area (TCVAI/BSA). Echocardiography reports were reviewed for chamber dilation and left ventricular hypertrophy (LVH), collectively defined as cardiomegaly. Associations between TCVAI/BSA and echocardiographic findings were assessed using correlation, ordinal regression, and receiver operating characteristic (ROC). Interscan repeatability was evaluated in 248 patients with 544 repeat CT examinations. Prespecified sex-specific thresholds were tested in a temporally independent validation cohort of 50 patients. Results Median TCVAI was higher in patients with cardiomegaly than those without (1061.9 vs 798.4 mL; P &lt; .001). TCVAI/BSA was associated with chamber dilation and LVH severity on univariate analysis and remained associated in multivariable ordinal models, except for right ventricular dilation. Discriminatory performance was fair to good, with area under the curve (AUC) 0.81 (95% CI, 0.75-0.87) in men and 0.77 (95% CI, 0.69-0.85) in women. Interscan repeatability was excellent (intraclass correlation coefficient [ICC]: 0.93). In independent validation, performance ranged from sensitivity 89.3%/specificity 27.3% at a high-sensitivity threshold to sensitivity 28.6%/specificity 100% at a high-specificity threshold. Conclusion AI-derived cardiac volume from routine chest CT shows fair to good performance for identifying echocardiography-defined cardiomegaly with high measurement repeatability, supporting a potential role for automated cardiac volumetry as an objective, opportunistic biomarker.
Long-term Results of the North American Phase II Transanal Total Mesorectal Excision Multicenter Trial for Rectal Cancer
Donovan, Katherine F., Chadi, Sami A. , Ricardo, Alison, Bonaccorso, Antoinette, Tomada, Elisa Paoluzzi , Sands, Dana R., Jh, Marks, Maykel, Justin A. , Alavi, Karim, Zaghiyan, Karen , Whiteford, Mark, McLemore, Elisabeth C. , Shawki, Sherief , Steele, Scott, Pigazzi, Alessio , Albert, Matthew, DeBeche-Adams, Teresa, Wexner, Steven, Sylla, P., Carmichael, Heather , Whiteford, Mark H., Albert, Matthew R. , deBeche-Adams, Teresa , Avery, Lisa M. , Wexner, Steven

Mayo Clinic

Annals of Surgery | March 3, 2026 | Volume: 284 | Issue: 2 | Pages: 236-243

10.1097/sla.0000000000007044 | PMID 41773887 Get It

Background: Transanal total mesorectal excision (taTME) facilitates sphincter preservation in low rectal cancer. Preliminary results and functional outcomes from the North American multicenter phase II taTME trial (NCT03144765) have been published. Three-year outcomes are reported. Methods: Patients with stage I to III rectal adenocarcinoma were enrolled across 11 centers (2017–2022). Endpoints included TME grade, 3-year overall survival, disease-free survival, cancer-specific survival, recurrence, late (beyond 90 d) complications, and stoma-free survival. Surveillance followed National Comprehensive Cancer Network guidelines, with pelvic magnetic resonance imaging (MRI) at 3 years to assess for pelvic sidewall recurrence when possible. Kaplan–Meier analysis assessed oncologic outcomes. Results: One hundred patients underwent taTME for tumors at a median of 5.8 cm from the anal verge, with intersphincteric resection in 36% and handsewn anastomosis in 54%. Median follow-up was 50.9 months. Late complications occurred in 32 patients, including 21 severe (Clavien-Dindo ≥3). Late anastomotic complications occurred in 5 patients; one required surgical revision. Estimated 3-year overall survival, cancer-specific survival, and disease-free survival were 93.7%, 96.6%, and 84.6%, respectively. Distant recurrence occurred in 15 patients (median: 17.6 months), most commonly in the lung and liver. Locoregional recurrence occurred in 2 patients. Preoperative N stage, lymph node yield, tumor deposits, and perineural invasion were associated with recurrence. Among 100 patients diverted at taTME, 97% were stoma-free at 3 years; 4 patients later underwent secondary diversion. Conclusions: Three-year outcomes of this multicenter trial support the safety and efficacy of taTME in resectable mid and low rectal tumors, with outcomes comparable to contemporary studies. Longer-term oncologic and functional outcomes are needed.
Phase 1, dose-escalation study of KTX-2001 (an NSD2 inhibitor) alone and in combination with darolutamide for metastatic castration-resistant prostate cancer.
Abida, Wassim , Aggarwal, Rahul Raj, Kouchkovsky, Ivan de, Cerda, Jose De La , Armstrong, Andrew J., Shore, Neal D., Stein, Mark N. , Coyne, Geraldine Helen O'Sullivan, Bicer, Fuat , Mortazavi, Amir, Heath, Elisabeth I. , Barnett, Miriam, Flynt, J. Erin, Sridharan, Vinidhra, Armstrong, Andrew J. , Armstrong, Andrew J , Kouchkovsky, Ivan de , Lang, Joshua M. , McManus, Hannah D. , Shore, Neal D. , Wei, Alexander Z. , Bilušić, Marijo , O'Sullivan Coyne, Geraldine , Mortazavi, Amir , Flynt, Erin , Redman, Jason Mark , Wise, David R

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps276 Get It

TPS276 Background: Metastatic castration-resistant prostate cancer (mCRPC) can evolve into a neuroendocrine-like subtype with aggressive behavior and poor outcomes (1). Nuclear Receptor-Binding SET Domain Protein 2 (NSD2) is overexpressed in prostate cancer and is a driver of both androgen-receptor (AR)-dependent signaling and of neuroendocrine differentiation, where cancer cells lose AR dependence and response to AR pathway inhibitors (ARPIs) (2,3,4). In studies of patient-derived neuroendocrine prostate cancer (NEPC) models, genetic depletion of NSD2 led to restoration of AR expression, reversal of adeno-to-neuroendocrine differentiation, and re-sensitization to ARPI (4). We hypothesize that NSD2 inhibition can reverse resistance to ARPIs in patients with progressive mCRPC, including with neuroendocrine differentiation. KTX-2001 is an oral, potent and selective small molecule inhibitor of NSD2. It is the sponsor’s second NSD2 inhibitor to enter the clinic. The sponsor’s first in class NSD2 inhibitor, KTX-1001, was shown to be tolerable and have preliminary efficacy in patients with relapsed/refractory multiple myeloma (5). Methods: STRIKE-001 (NCT07103018) is a multicenter, open-label phase 1 dose escalation trial of KTX-2001 monotherapy (Part A) and KTX-2001 + darolutamide (Part B). Key inclusion criteria are males age ≥18 years with mCRPC, progression after receiving ARPI, Eastern Cooperative Oncology Group performance score of 0-1, willingness to undergo biopsy if safe and feasible, and life expectancy of ≥6 months. Participants take KTX-2001 by mouth once daily alone (Part A) or with darolutamide 600 mg twice daily (Part B). Dose escalation of KTX-2001 in Parts A and B will follow a 3+3 design and occur in parallel at multiple planned dose levels. Primary objectives are to assess the safety and tolerability, determine MTD, and determine RP2D(s) for further study of KTX-2001 alone and in combination with darolutamide. Secondary objectives include characterization of efficacy and PK parameters for both KTX-2001 monotherapy and in combination with darolutamide. Exploratory objectives include study of pharmacodynamic effects, circulating tumor cells, and cell-free DNA. 1. Conteduca V, Eur J Cancer 2019. 2. Parolia A, Nat Genet 2024. 3. Aytes A, Nat Commun 2018 4. Li J, bioRxiv 2023.07.18.549585 5. Bories P, Blood Vol 144, Suppl 1,2024. Clinical trial information: NCT07103018 .
Abstract PS3-06-08: Somatic variant detection using long read RNA sequencing reveals HLA-restricted targets for immunotherapy
Henry, S., Zhang, Y., Foster, Rachel H. , Gayton, J. M., Hostal, A., Wilson, E. A., Gustafson, Michael P. , Pockaj, Barbara A. , Park, J., Anderson, K. S., Batalini, Felipe , Foster, R., Singharoy, Abhishek

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS3-06-08-PS3-06-08

10.1158/1557-3265.sabcs25-ps3-06-08 Get It

Abstract Introduction: Accurate detection and prioritization of tumor-specific somatic variants is foundational to the development of personalized immunotherapies. Traditional pipelines for neoepitope identification rely heavily on short-read next-generation sequencing (NGS) and DNA-based variant calling, followed by RNA expression filtering and HLA-binding prediction. However, this approach is limited by time-intensive workflows, potential false positives from DNA-only calls, and poor capture of complex isoforms or RNA-level editing. Moreover, the accuracy of neoepitope prediction is constrained by conventional sequence-based HLA binding algorithms that do not account for structural and biophysical features of peptide-MHC interactions, particularly across underrepresented HLA alleles. Methods: To overcome these limitations, we developed a streamlined, sequencing-to-vaccine framework that leverages long-read RNA sequencing for direct detection of expressed somatic variants, including fusions, indels, and single nucleotide variants. Using Oxford Nanopore Technologies’ cDNA-PCR approach, we enable comprehensive, full-length transcript characterization from both fresh and frozen breast tumor samples. Our bioinformatic pipeline, NeoTarget, integrates alignment, variant calling, and neoepitope inference from tumor RNA in a single, modular workflow. A core innovation of this pipeline is HLA-Inception, a deep convolutional neural network trained to predict peptide-MHC class I binding using features derived from molecular dynamics-based modeling of electrostatic potential at the peptide-HLA interface, enhancing generalizability across diverse HLA subtypes. Results: Expanding on previous results, the current NeoTarget pipeline identifies, evaluates, and prioritizes single nucleotide variants, indels, and fusions. To validate this system, we used a set of 9 human breast cancer tumors benchmarked with short read sequencing. Identified neoantigens included most variants shown by clinical short read sequencing and also novel structural variants (i.e., fusions) only revealed with long read sequencing with high confidence. Conclusion: Here, we describe the design and performance of the NeoTarget pipeline, and show proof-of-concept feasibility of applying this fast and cost-effective workflow for HLA-restricted epitope discovery in breast tumors using long-read RNA sequencing. Overall, these methods can be applied to rapidly identify and prioritize neoantigens for personalized neoantigen-based immune therapies. Citation Format: F. Batalini, S. Henry, Y. Zhang, R. Foster, J. M. Gayton, A. Hostal, E. A. Wilson, A. Singharoy, M. Gustafson, B. Pockaj, J. Park, K. S. Anderson. Somatic variant detection using long read RNA sequencing reveals HLA-restricted targets for immunotherapy [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-06-08.